Fundz
Funding, M&A and exec moves matched to your market — guaranteed to pay for itself in a year, or we refund it. See terms for full details.See plans →

BIOCAPTIVA raises £1.5 million in a funding round to drive international growth. The round is led by experienced executives aiming to enhance the company's cancer liquid biopsy technology's commercial adoption.

PRIVATEAug 16, 2026•about 5 hours ago

Amount Raised

£1.5 Million

Round Type

Seed

EdinburghHealth Care

Description

University of Edinburgh spin-out BIOCAPTIVA has secured £1.5 million in a recent funding round to accelerate international growth. The firm has recently launched its cancer liquid biopsy technology platform and received ISO 13485 certification. The new capital will help expand its impact across cfDNA sequencing applications. Experienced life sciences executive Stephane Argivier has been appointed as the new chair.

Company Information

Company

BIOCAPTIVA

Location

Edinburgh, Scotland, United Kingdom

About

BIOCAPTIVA is developing the BioCaptis, a revolutionary medical device which has the potential to transform liquid biopsy testing for cancer management, by improving early diagnosis and monitoring of disease and enhancing clinical trial data of cancer patients. The BioCaptis captures up to 100x more cell free DNA (cfDNA) than a venous blood draw, yielding cfDNA in high quality and quantity for testing, addressing the major challenge of liquid biopsy in cancer management. This will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients. BIOCAPTIVA was founded in 2021 when it spun out from the University of Edinburgh. BIOCAPTIVA is based in Edinburgh and backed by Archangels Scottish Enterprise, Cancer Research Horizons, the new innovation engine of Cancer Research UK and Old College Capital, the University of Edinburgh's in-house venture investment fund. For more information, please visit www.biocaptiva.com and follow us on LinkedIn

Don't miss BIOCAPTIVA's next move

Get an email the moment BIOCAPTIVA raises, hires an exec, or expands — usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for BIOCAPTIVA's next move

Learn about Strategic plan

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.